Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Hypoplastic Left Heart Syndrome Clinical Trial

Official title:

Evaluation of Outcomes of Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06342999
• Other study ID #: 22-012399
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2024
• Est. completion date: July 2035

Study information

• Verified date: April 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).

Description:

The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: July 2035
• Est. primary completion date: July 2035
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A to 45 Years

Eligibility

Inclusion Criteria

• Pregnant women 18-45 years of age.

• Gestational age between 21 0/7 and 29 6/7 weeks of gestation

• The mother must be healthy enough to undergo surgery.

• The individual being enrolled must be able to provide informed consent.

• Dominant cardiac defect is valvar

• Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:

• Retrograde flow in the transverse aortic arch

• Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.

• Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:

• Left ventricle long axis Z-score more than zero

• Left ventricle short axis Z-score more than zero

• Aortic annulus Z-score more than -3.5

• Mitral valve annulus Z-score more than -2

• Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).

Exclusion Criteria

• Patient is less than 18 years of age or more than 45 years of age.

• Contraindication to anesthesia or surgery

• Preterm labor or cervical length <20 mm at enrollement or uterine anomaly strongly predisposing to preterm delivery.

• Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)

• Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.

• Cases with all the following criteria:

• Left ventricle pressure = 47 mmHg

• MV dimension Z-score < 0.1

• MV inflow time Z-score < -2

Related Conditions & MeSH terms

• Hypoplastic Left Heart Syndrome
• Syndrome

Intervention

Procedure:
• Fetal Aortic Valvuloplasty Procedure
Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.

Device:
• Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter
Balloon Catheter
• Trek RX and Mini Trek RX Coronary Dilatation Catheter
Coronary Dilation Catheter

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mauro H. Schenone

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of cases in which the procedure was successful	Procedure success defined as the aortic valve was crossed and the balloon inflated with clear evidence of improvement of blood flow through the aortic valve and or new aortic valve regurgitation	Baseline
Primary	Number of cases in which a biventricular repair was achieved		Baseline
Primary	Number cases with pulmonary hypertension		Baseline
Secondary	Number of cases delivered prematurely		Baseline
Secondary	Number of cases with perinatal death		Baseline
Secondary	Number of maternal complications		Baseline